News

Public · Published

Morgan Stanley maintains CRH at Overweight, lowers price target to $129 from $139

Morgan Stanley maintained its Overweight rating on CRH but lowered its price target to $129 from $139, a 7.2% decrease. The revised target implies 37.9% upside from CRH's November 3 close of $93.53.

Published:

Updated:

What happened

Morgan Stanley maintained its Overweight rating on CRH but lowered its price target to $129 from $139, a 7.2% decrease. The revised target implies 37.9% upside from CRH’s November 3 close of $93.53.

Confirmed

Global impact / market context

A lower target can influence investor expectations by reducing the value Morgan Stanley assigns to CRH shares, potentially affecting demand for the stock. The rating stayed Overweight, however, and the article reports no change to CRH’s operations, revenue, costs, or capital spending.

Analyst inference

The article lists five recent analyst targets between $100 and $120, below Morgan Stanley’s new $129 target. This comparison places Morgan Stanley’s estimate above those listed views, even after its reduction; it does not establish what investors will pay for CRH shares.

Analyst inference

What to watch

  1. Whether Morgan Stanley later explains the target cut or changes its Overweight rating; either could clarify how its revised view might influence investor expectations for CRH shares. Analyst inference
  2. Whether later analyst notes move targets toward or away from Morgan Stanley’s $129 figure, as changes in published estimates can shape expectations and demand for CRH shares. Analyst inference
  3. How CRH’s share price compares with the revised $129 target and the cited November 3 close of $93.53; the article’s 37.9% implied upside uses that past close. Analyst inference

Evidence

  • Original source link unavailable